"In response to the need for mRNA COVID-19 vaccines during the pandemic ... and end-to-end RNA expertise under one roof, ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward ...

This year's headlines on COVID-19 featured new research on COVID-related mortality, post-acute sequelae of infection, vaccine ...

The study was conducted between 2021 and 2023, during the height of the COVID-19 global pandemic ... Prevention during the ...

Two Kansas State University faculty members, both from the College of Veterinary Medicine, will each receive a $5,000 award in recognition of their outstanding teaching and research.

Aligos Therapeutics, Inc. ( (ALGS) ) has released its Q3 earnings. Here is a breakdown of the information Aligos Therapeutics, Inc. presented ...

A critical challenge during the early COVID-19 pandemic was determining whether a patient would survive the infection or die ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

Former IT specialist Lisa Domski had worked at Blue Cross for more than 30 years and worked 100% remotely during the pandemic. She said the vaccine went against her Catholic beliefs. The ruling could ...

About Checkpoint Therapeutics Checkpoint Therapeutics ... including the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones.